Bioventus BVS 深 沪
等待开盘 10-16 09:30:00 美东时间
13.81
+0.310
+2.30%
华盛通- 最 高13.91
- 今 开13.73
- 成交量 29.56万股
- 最 低 13.685
- 昨 收 13.50
- 总市值 116.13万
- 52周最高 15.8927
- 市盈率 静 41.86
- 换手率 0.35%
- 52周最低 6.47
- 委 比 -91.53%
- 总股本 8.41万
- 历史最高 19.941
- 量 比 0.83
- 振 幅 1.67%
- 历史最低 0.7999
- 每 手 1
- 风险率 2.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
Cantor Fitzgerald Reiterates Overweight on Bioventus, Maintains $15 Price Target
Cantor Fitzgerald analyst Sarah James reiterates Bioventus (NASDAQ:BVS) with a Overweight and maintains $15 price target.
08-17 19:57
Bioventus shares are trading higher after the company reported strong Q2 financial results and announced a review of strategic alternatives.
Bioventus shares are trading higher after the company reported strong Q2 financial results and announced a review of strategic alternatives.
08-05 23:00
Bioventus Q2 Adj. EPS $0.22, Inline, Sales $153.208M Miss $155.640M Estimate
Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.22 per share which met the analyst consensus estimate. This is a 4.76 percent increase over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $153.208 million which missed the analyst consensus...
08-05 19:34
Bioventus Affirms FY2026 Adj EPS Guidance of $0.75-$0.79 vs $0.78 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $605.756M Est
Bioventus (NASDAQ:BVS) affirms FY2026 Adj EPS guidance from $0.75-$0.79 to $0.75-$0.79 vs $0.78 analyst estimate. Affirms FY2026 sales outlook from $600.000 million-$610.000 million to $600.000 million-$610.000 million vs $605.756 million estimate.
08-05 19:31
Why Forte Biosciences Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket
Shares of Forte Biosciences Inc (NASDAQ:FBRX) rose sharply in pre-market trading after argenx SE – ADR (NASDAQ:ARGX) announced plans to acquire the company for $77 per share in cash, valuing the deal at $2.2 billion. Forte Biosciences shares jumped 38.9% to $76.10 in pre-market trading. Here are som...
07-27 17:09
Did Bioventus Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be r...
07-04 00:24
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
Bioventus Inc. announced that Mark Singleton, its Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 8, 2026, at 4:00 p.m. ET. A live webcast will be available on the company’s website, www.bioventus.com, with a replay following the event. Bioventus, a global leader in innovations for active healing, focuses on delivering cost-effective, clinically prove...
06-02 11:00
Transcript: Bioventus Q1 2026 Earnings Conference Call
Bioventus (NASDAQ:BVS) released first-quarter financial results and hosted an e...
06-01 18:46
